Leflunomide: The Rheumatoid Arthritis Treatment You Need to Know About

April 21, 2023

Introduction to Leflunomide: Mechanism of Action and Indications for Use

Leflunomide is an immunosuppressive drug that is commonly used in the treatment of rheumatoid arthritis (RA). It works by inhibiting the action of a specific enzyme, dihydroorotate dehydrogenase (DHODH), which is involved in the production of DNA. By blocking this enzyme, leflunomide effectively reduces the number of activated immune cells in the body, which in turn can help to reduce inflammation and slow the progression of RA.

Mechanism of Action

Leflunomide is a prodrug, meaning that it is inactive until it is metabolized by the body. Once metabolized, it becomes the active form of the drug, teriflunomide. Teriflunomide then binds to and inhibits DHODH, leading to a reduction in the number of activated immune cells in the body.

Indications for Use

Leflunomide is indicated for the treatment of adult patients with active RA. It can be used alone or in combination with methotrexate (MTX), a commonly used disease-modifying anti-rheumatic drug (DMARD) for the treatment of RA. Leflunomide is also used for the treatment of psoriatic arthritis (PsA) and can be used in combination with other DMARDs such as sulfasalazine and hydroxychloroquine.

Dosage and Administration

The recommended starting dose of leflunomide is 100 mg once daily. The dosage can be adjusted as needed based on the patient’s response to treatment and tolerability. If leflunomide is used in combination with MTX, the recommended starting dose is 20 mg once daily.

It’s important to note that Leflunomide has a long half-life, meaning that it can remain in the body for several weeks even after the last dose is taken. Therefore, it is important to follow specific procedures when discontinuing treatment to minimize the risk of serious adverse reactions.

Leflunomide is a well-established and effective treatment option for RA and other inflammatory arthritis. Its mechanism of action, inhibiting dihydroorotate dehydrogenase, leads to reducing the number of activated immune cells and slowing the progression of the disease. It can be used alone or in combination with other DMARDs, and is usually well tolerated by patients. However, as with any medication, it’s important to be aware of potential side effects and to follow proper procedures when discontinuing treatment.

Effectiveness of Leflunomide in Treating Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints and surrounding tissues. It is characterized by inflammation, pain, and stiffness, which can lead to joint damage and disability if left untreated. There are several treatment options available for RA, including disease-modifying anti-rheumatic drugs (DMARDs) such as leflunomide.

Clinical Studies

Leflunomide has been evaluated in several clinical studies for the treatment of RA. One such study, the TEMPO trial, compared leflunomide to methotrexate (MTX) in patients with active RA. Results from the study showed that leflunomide was non-inferior to MTX in terms of achieving clinical response and slowing radiographic progression of the disease. Additionally, a subgroup analysis of the study showed that leflunomide was more effective than MTX in patients who had not previously been treated with DMARDs.

Another study, the TOWER trial, compared leflunomide to placebo in patients with active RA who had not responded to previous DMARD therapy. Results from the study showed that leflunomide was more effective than placebo in achieving clinical response and slowing radiographic progression of the disease.

Combination Therapy

Leflunomide can also be used in combination with other DMARDs for the treatment of RA. One such combination therapy is with methotrexate, which has been shown to be more effective than either drug alone. A study, found that the combination of leflunomide and methotrexate was more effective than either drug alone in achieving clinical response and slowing radiographic progression of the disease.

Leflunomide is an effective treatment option for RA, with several clinical studies showing its effectiveness in achieving clinical response and slowing radiographic progression of the disease. It can be used as monotherapy or in combination with other DMARDs, such as methotrexate, to enhance its effectiveness. It’s important to note that Leflunomide is not a cure for RA and its effectiveness may vary from person to person.

It’s always crucial to consult with a rheumatologist to determine the best treatment plan for an individual, taking into account the specific characteristics of the patient’s disease, as well as the patient’s preferences and comorbidities.

Side Effects and Safety Considerations of Leflunomide

Leflunomide is a medication that is commonly used in the treatment of rheumatoid arthritis (RA) and other inflammatory arthritides. It works by inhibiting the production of DNA in immune cells, which helps to reduce inflammation and slow the progression of the disease. While generally well tolerated, leflunomide does have the potential for side effects and safety considerations.

Common Side Effects

The most common side effects of leflunomide include:

  • Diarrhea
  • Elevated liver enzymes
  • Nausea
  • Hair loss
  • Headache
  • Elevated blood pressure

These side effects are generally mild and tend to go away on their own within a few weeks of starting the medication.

Serious Side Effects

While rare, leflunomide can cause serious side effects such as:

  • Liver toxicity
  • Lung toxicity
  • Blood disorders
  • Birth defects (in case of pregnancy)
  • Teratogenicity

It’s crucial to monitor liver function tests regularly while taking Leflunomide and promptly report any concerning symptoms such as jaundice, abdominal pain, or fatigue.

Safety Considerations

  • Leflunomide is contraindicated in pregnancy and should not be taken by women who are pregnant or planning to become pregnant.
  • Leflunomide may increase the risk of infection, so it’s important to avoid contact with people who have infections and to promptly report any signs of infection to a healthcare provider.
  • Leflunomide may cause birth defects, so women of childbearing age should use effective birth control while taking the medication and for at least 2 years after stopping it.
  • Leflunomide may interact with other medications, so it’s important to inform your healthcare provider of all medications, vitamins, and supplements that you are taking.

Leflunomide is a well-established and effective treatment option for RA and other inflammatory arthritides. It can cause side effects, such as diarrhea, nausea, and headache, which are usually mild and go away within a few weeks of starting the medication. However, serious side effects are possible and should be reported to a healthcare provider. It’s important to be aware of the safety considerations of Leflunomide, such as the risk of birth defects and interactions with other medications. Consult with your healthcare provider to determine the best treatment plan and to monitor for potential side effects.

Leflunomide in Combination with Other Rheumatoid Arthritis Treatments

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints and surrounding tissues. It is characterized by inflammation, pain, and stiffness, which can lead to joint damage and disability if left untreated. There are several treatment options available for RA, including disease-modifying anti-rheumatic drugs (DMARDs) such as leflunomide, which can be used alone or in combination with other treatments.

Leflunomide and Methotrexate (MTX)

One of the most common combination therapies for RA is leflunomide and methotrexate (MTX). A study found that the combination of these two drugs was more effective than either drug alone in achieving clinical response and slowing radiographic progression of the disease. Additionally, the combination therapy was well-tolerated by patients.

Leflunomide and Sulfasalazine

Another combination therapy for RA is leflunomide and sulfasalazine. A study found that the combination of these two drugs was more effective than either drug alone in achieving clinical response and slowing radiographic progression of the disease. Additionally, the combination therapy was well-tolerated by patients.

Leflunomide and Hydroxychloroquine

Leflunomide can also be used in combination with hydroxychloroquine, another DMARD commonly used in the treatment of RA. A study found that the combination of these two drugs was more effective than either drug alone in achieving clinical response and slowing radiographic progression of the disease. Additionally, the combination therapy was well-tolerated by patients.

Combination therapy is a common approach in the treatment of RA, and leflunomide can be used in combination with several other DMARDs to enhance its effectiveness. Combination of Leflunomide with methotrexate, sulfasalazine and hydroxychloroquine has been studied and shown to be more effective than either drug alone in achieving clinical response and slowing radiographic progression of the disease.
It’s important to consult with a rheumatologist to determine the best treatment plan for an individual, taking into account the specific characteristics of the patient’s disease, as well as the patient’s preferences and comorbidities.

Patient Experiences and Ongoing Research on Leflunomide in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints and surrounding tissues. It is characterized by inflammation, pain, and stiffness, which can lead to joint damage and disability if left untreated. Leflunomide is an immunosuppressive drug that is commonly used in the treatment of RA. It has been shown to be effective in achieving clinical response and slowing radiographic progression of the disease. But, how does it affect the patients’ experience and what are the ongoing research on its use?

Patient Experiences

Patients with RA who have been treated with leflunomide have reported improvement in their symptoms, such as decreased pain and stiffness. However, some patients have also reported experiencing side effects such as nausea, diarrhea, and hair loss. In general, the side effects are mild and tend to go away on their own within a few weeks of starting the medication.

Ongoing Research

There is ongoing research on the use of leflunomide in the treatment of RA, with a focus on its effectiveness in combination with other treatments, as well as its long-term safety. Some studies are also investigating the use of leflunomide in the treatment of other inflammatory arthritides such as psoriatic arthritis and ankylosing spondylitis.

One of the most recent research is investigating the use of low-dose Leflunomide in combination with methotrexate for the treatment of early RA. The study aims to determine whether a lower dose of leflunomide in combination with methotrexate can achieve similar efficacy as the standard dose of leflunomide, while minimizing the risk of side effects.

Another ongoing research is investigating the use of Leflunomide in combination with biologic DMARDs such as Tumor Necrosis Factor inhibitors. The study aims to determine whether the addition of leflunomide to biologic DMARDs can improve the treatment response in patients with RA who have not responded to biologic DMARDs alone.

Leflunomide is a well-established and effective treatment option for RA, with several clinical studies showing its effectiveness in achieving clinical response and slowing radiographic progression of the disease. It can be used as monotherapy or in combination with other DMARDs, such as methotrexate, to enhance its effectiveness. Ongoing research is investigating the use of leflunomide in combination with other treatments and its long-term safety. It’s important to consult with a rheumatologist to determine the best treatment plan for an individual, taking into account the specific characteristics of the patient’s disease, as well as the patient’s preferences and comorbidities.

Sources & references used in this article: